Furthermore, as there was no significant difference in plasma iFABP concentrations between samples collected at the end of EEN in patients with Crohn’s disease compared with Controls, one can argue that there was a decrease in plasma iFABP and improvement in small bowel damage during EEN, which we were unable to detect due inter-individual responses and the small sample. Here, FABP2 is linked to Crohn disease.